Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
about
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyClinico-pathological prognostic factors of renal cell carcinoma: A 15-year review from a single center in GreeceManagement of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Current status of targeted therapy for advanced renal cell carcinomaThe Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC).Poor Risk Advanced Renal Cell Carcinoma: Outcomes from a Registry in a Tertiary Cancer Center.Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
P2860
Q28547506-31B6267D-49FD-4AC4-9902-D76B2DEDA289Q33614217-52E59875-CAF8-41A8-B47F-66A68D6EE725Q34351372-8D0C144D-C268-41AE-AC43-DB61967B466AQ35903850-7C8ED6A5-24F8-405E-9724-4455EA528EDFQ37226025-4E7292C0-2BBA-4E51-881E-8F1FFBCC8DAFQ38624864-E0FF9FE5-73B1-45E6-97B4-0266ECF2FDC0Q38762066-027FD9F7-8C45-4B6B-8BD9-C5CC90411902Q39198025-7150FEDD-062E-449B-AE95-BC13CFC9C7D8Q43649965-86D6A269-D63D-4F61-A844-796DEA49FA71Q47147905-24D4E74F-F3A2-428A-B425-D590CCBF9511Q55021037-72D6CE28-F4ED-4BC4-A6B2-984C557DEAF0
P2860
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of vascula ...... cinoma and poor risk features.
@ast
Efficacy and safety of vascula ...... cinoma and poor risk features.
@en
type
label
Efficacy and safety of vascula ...... cinoma and poor risk features.
@ast
Efficacy and safety of vascula ...... cinoma and poor risk features.
@en
prefLabel
Efficacy and safety of vascula ...... cinoma and poor risk features.
@ast
Efficacy and safety of vascula ...... cinoma and poor risk features.
@en
P2093
P2860
P1476
Efficacy and safety of vascula ...... cinoma and poor risk features.
@en
P2093
Cheryn Song
Choung-Soo Kim
Hanjong Ahn
Jae-Lyun Lee
Jin-Hee Ahn
Jun Hyuk Hong
Kwonoh Park
Seongjoon Park
Tae-Won Kim
P2860
P2888
P304
P356
10.1007/S00432-012-1148-8
P50
P577
2012-01-12T00:00:00Z